| April 26, foreign investors in China's largest | | | | research company?? By Gus Medical Technology Co., |
| pharmaceutical merger baked: the largest U.S. drug | | | | Ltd. Wei Xiong, former general manager that, the |
| development company?? Charles Valley Laboratories | | | | company is at least in this country to carry out |
| (CharlesRiverLaboratoriesInternational (NYSE: CRL), | | | | large-scale "research group outsourcing" model of the |
| hereinafter referred to as "Charles River Valley") to | | | | first drug development company. |
| 1.6 billion U.S. dollars acquisition of Wuxi, WuXi | | | | According to data released WuXi PharmaTech, the |
| PharmaTech Co., Ltd. (NYSE: WX, hereinafter | | | | world's top 20 pharmaceutical companies in the 18 |
| referred to as "WuXi PharmaTech.") | | | | and the top 10 pharmaceutical companies in the nine |
| Charles River Valley 40 years in the last century by | | | | have become the company's customers. According |
| the founding father of JamesC.Foster, JamesC.Foster | | | | to WuXi PharmaTech 2009 Annual Report, revenues |
| led the company last year achieved revenue of 1.2 | | | | 270 million U.S. dollars, gross profit 108.3 million U.S. |
| billion, the company currently has 9,000 employees | | | | dollars. |
| around the world. WuXi PharmaTech is aestablished | | | | 5 6, Ge Li, the founder of WuXi PharmaTech |
| only 10 years, sales of 270 million U.S. dollars of | | | | accepted to be interviewed. Ge Li said that the |
| pharmaceutical R & D outsourcing company. This | | | | acquisition of Charles River Valley WuXi PharmaTech, |
| acquisition not only means WuXi PharmaTech's drug | | | | will WuXi PharmaTech's services from drug |
| development outsourcing, "China" model has been | | | | development to clinical trials, the most upstream |
| concerned at the same time, foreign investment | | | | development, integration, it was his expectation. By |
| enterprises in China's pharmaceutical R & D M | | | | then, the new company will have sales of 1.5 billion |
| & A curtain has quietly opened its industrial chain | | | | dollars, 1.2 million employees. After the merger, Ge Li |
| in the world of pharmaceutical outsourcing is more | | | | as the new executive vice president and global R |
| far-reaching. | | | | & D and China, president. |
| Drug development star appearance and exit | | | | Foreign investors step up action Before the |
| WuXi PharmaTech pioneered the outsourcing of drug | | | | acquisition of WuXi PharmaTech, China's foreign |
| development, "China" model, now, this model has | | | | acquisition comes as the pharmaceutical industry's |
| become a model for pharmaceutical R & D | | | | largest acquisition of Bayer Pharmaceuticals |
| enterprise. For this model, the largest | | | | Dongsheng the OTC business, the matter in March 4, |
| bio-pharmaceutical research and development | | | | 2008 ended, when the two sides stated that the |
| outsourcing company Biological Technology Co., Ltd. | | | | final Bayer invested 1.264 billion yuan to complete the |
| Nanjing Jin Sirui Shi Yan Ningbo vice president | | | | acquisition. But in the decades before and since, |
| explained: "To save costs, large pharmaceutical | | | | China's large-scale foreign investment has not |
| companies abroad, the drug reduced the employment | | | | expressed much interest in pharmaceutical companies. |
| of scientists, but the change WuXi PharmaTech | | | | In this regard, a veteran of pharmaceutical industry, |
| provided by the team of China's scientific research, | | | | large pharmaceutical companies in China actually is |
| undertake appropriate research and development | | | | inadequate. Large pharmaceutical companies abroad |
| expertise. "WuXi PharmaTech to the main reason for | | | | each year can be introduced several innovative |
| success is the company in the domestic first carried | | | | medicines, with a strong R & D capability, and |
| out in strict accordance with international standards, | | | | China's innovative drugs (a class of drugs) every year |
| large-scale research and development. | | | | but one or two, once vacant and even a few years |
| WuXi PharmaTech and even foreign companies | | | | ago, the lack of R & D . |
| according to different groups, such as Merck Group, | | | | Have engaged in drug development industry, Bayer |
| Pfizer Group, etc., and signed with these companies | | | | (China), former general manager, Group CEO Gao |
| for several years, outsourcing agreement. Meanwhile, | | | | Zhan good doctor that the Charles River Valley see is |
| the group researchers as research and development | | | | the pattern established by WuXi PharmaTech and |
| of these large companies "brain trust" at any time | | | | Chinese low-cost human resources. If your in China |
| with these companies to open R & D | | | | and WuXi PharmaTech to establish a competing |
| conference, in accordance with the requirements of a | | | | company, it would be time consuming and more risky |
| key R & D experiment. The largest clinical | | | | things, the acquisition much easier. |